National Institute of Health Leish-111F + MPL-SE Vaccine Trials Persistent Records:
Safety and Efficacy of Immunogenicity in Mucocutaneous Leishmaniasis in Infected Adults
Safety and Efficacy of Immunogenicity of Cutaneous Leishmaniasis Vaccine in Infected Adults
Prevention of Cutaneous Leishmaniasis in Previously Exposed Healthy Subjects
Prevention of Cutaneous Leishmaniasis in Healthy Adults NOT Previously Exposed
Campos-Neto A, Webb JR, Greeson K, Coler RN, Skeiky YA, Reed SG. "Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice." Infection and Immunity. June 2002; 70(6):2828-36
Kenney RT, Sacks DL, Sypek JP, Vilela L, Gam AA, Evans-Davis K. "Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis." The Journal of Immunology. Oct 15 1999;163(8):4481-8.
Saldarriaga OA, Travi BL, Park W, Perez LE, Melby PC. " Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs." Mar 10 2006;24(11):1928-40
Convit J, et. al. "Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin - Preliminary report" Mem. Inst. Oswaldo Cruz. [online]. Feb. 2004, vol.99, no.1 [cited 11 June 2006], p.57-62. Available Online: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762004000100010&lng=en&nrm=iso
Kamil AA, et. al. "Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guerrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers." Transactions of the Royal Society of Tropical Medicine and Hygiene. May-June 2003;97(3):365-8
Khamesipour A, Dowlati Y, Asilian A, Hashemi-Fesharki R, Javadi A, Noazin S, Modabber F. "Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis." Vaccine. May 25 2005; 23(28):3642-8.
Mahmoodi M, Khamesipour A, Dowlati Y, Rafati S, Momeni AZ, Emamjome h M, Hejazi H, Modabber F. "Immune response measured in human volunteers vaccinated with autoclaved Leish mania major vaccine mixed with low dose of BCG." Clinical and Experimental Immunology. November 2003;134(2):303-8
Momeni A., et. al. "A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran" Vaccine. February 1999, 17(5): 466-472
Articles, Reports and Reviews:
Brodskyn C, de Oliveira CI, Barral A, Barral-Netto M. "Vaccines in leishmaniasis: advances in the last five years." Expert Review of Vaccines. October 2003;2(5):705-17
Coler RN, Reed SG. "Second-generation vaccines against leishmaniasis" Trends in Parasitology. May 2005;21(5):244-9.
Dumonteil, McMahon-Pratt, Price. "Report of the Fourth
Leishmaniasis" UNDP/World Bank/WHO Special Programme for Research & Training in Tropical Diseases (TDR). May 2001;
Enserink M. "Infectious diseases. Sand fly saliva may be key to new vaccine." Science. August 10 2001;293(5532):1028.
Genaro O. et. al. "Vaccine for Prophylaxis and Immunotherapy, Brazil." Clinics in Dermatology. 1996; 14:503-512
Ravindran R, Ali N. "Progress in vaccine research and possible effector mechanisms in visceral leishmaniasis." Current Molecular Medicine. September 2005;4(6):697-709
Reithinger R, Davies CR. "Canine leishmaniasis: novel strategies for control." Trends in Parasitology. July 2002;18(7):289-90.
Requena JM, Iborra S, Carrion J, Alonso C, Soto M. "Recent advances in vaccines for leishmaniasis." Expert Opinion on Biological Therapy. September 2004;4(9):1505-17
Rocha LG, Almeida JR, Ma cedo RO, Barbosa-Filho JM. "A review of natural products with antileishmanial activity." Phytomedicine. June 2005;12(6-7):514-35
Vanloubbeeck Y, Jones DE. "The immunology of Leishmania infection and the implications for vaccine development." Annals of the New York Academy of Sciences. October 2004;1026:267-72